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Anti-neutrophil cytoplasmic autoantibodies (ANCA) targeting proteinase 3 (PR3) and 
myeloperoxidase expressed by innate immune cells (neutrophils and monocytes) are 
salient diagnostic and pathogenic features of small vessel vasculitis, comprising granulo-
matosis with polyangiitis (GPA), microscopic polyangiitis, and eosinophilic GPA. Genetic 
studies suggest that ANCA-associated vasculitides (AAV) constitute separate diseases, 
which share common immunological and pathological features, but are otherwise het-
erogeneous. The successful therapeutic use of anti-CD20 antibodies emphasizes the 
prominent role of ANCA and possibly other autoantibodies in the pathogenesis of AAV. 
However, to elucidate causal effects in AAV, a better understanding of the complex inter-
play leading to the emergence of B lymphocytes that produce pathogenic ANCA remains 
a challenge. Different scenarios seem possible; e.g., the break of tolerance induced by 
a shift from non-pathogenic toward pathogenic autoantigen epitopes in inflamed tissue. 
This review gives a brief overview on current knowledge about genetic and epigenetic 
factors, barrier dysfunction and chronic non-resolving inflammation, necro-inflammatory 
auto-amplification of cellular death and inflammation, altered autoantigen presentation, 
alternative complement pathway activation, alterations within peripheral and inflamed 
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tissue-residing T- and B-cell populations, ectopic lymphoid tissue neoformation, the 
characterization of PR3-specific T-cells, properties of ANCA, links between autoimmune 
disease and infection-triggered pathology, and animal models in AAV.
Keywords: anti-neutrophil cytoplasmic autoantibodies, anti-neutrophil cytoplasmic autoantibody vasculitides, 
microscopic polyangiitis, granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis
inTRODUCTiOn
Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated 
vasculitides (AAV) are classified into three distinct diseases 
based on clinical and pathological features: granulomatosis with 
polyangiitis (GPA, formerly Wegener’s granulomatosis), micro-
scopic polyangiitis (MPA), and eosinophilic granulomatosis with 
polyangiitis (EGPA, Churg–Strauss syndrome). Etiology and 
pathogenesis of AAV are multifactorial (1, 2). The pathogenesis 
appears to be initiated by a combination of predisposing genetic 
and environmental factors, altered autoantigen presentation, 
ectopic lymphoid tissue neoformation, and imbalance of effec-
tor and regulatory B- and T-cells. Consequently, production of 
pathogenic autoantibodies originating from precursor natural 
autoantibodies results in ANCA-induced activation of neutro-
phils and monocytes with subsequent activation of the alternative 
complement pathway, vascular damage, and self-perpetuating 
non-resolving chronic inflammation (2–4). Herein, we briefly 
summarize current ideas, observations, and evidence on the 
pathogenesis of AAV.
CLiniCAL MAniFeSTATiOnS
While each of the three AAV retains a unique clinical pheno-
type, many manifestations are shared among them owing to the 
systemic nature of the underlying small-vessel vasculitis, and, 
in GPA and EGPA, granulomatous inflammation. Thus, pul-
monary–renal syndrome is the dominating clinical feature in 
GPA and MPA (5, 6). In EGPA, renal involvement is associated 
with positive ANCA-status (7, 8). Prodromes such as malaise, 
arthralgias, myalgias—and rhinitis and/or sinusitis in GPA and 
EGPA—often precede manifestations of the pulmonary–renal 
syndrome by weeks or months (5–7). Fulminant AAV is rare 
(9). EGPA patients typically have a long-standing history of 
asthma and allergic rhinitis (7, 10). Other organs frequently 
affected are peripheral and central nervous system, skin, gut, 
and heart (5–7). Laboratory findings show elevated markers of 
inflammation (3, 11). GPA is highly associated with proteinase 
3 (PR3)-specific ANCA, whereas MPA and—less commonly—
EGPA are associated with myeloperoxidase (MPO)-specific 
ANCA (12–14). The majority of AAV patients (approximately 
80–90%) present with renal or other organ-threatening mani-
festations, i.e., generalized disease. Relapse is more common in 
GPA (15). Renal-limited AAV is less common. Fewer than 10% 
of patients have a localized phenotype restricted to the upper 
and/or lower respiratory tract or early-systemic phenotype 
without imminent organ failure with less frequently detected 
ANCA (5, 11, 12, 16, 17). Progression from localized to general-
ized GPA is rare (16).
Treatment is guided by severity of organ involvement and 
disease activity. Various cytotoxic immunosuppressants and the 
monoclonal anti-CD20 antibody rituximab are recommended 
for the induction and maintenance of remission (18, 19). While 
treatment options have improved the prognosis of AAV, therapy 
de-escalation still carries an immanent risk of relapse (20). Major 
causes of death are vasculitis and infections (21). Optimizing treat-
ment strategies according to prognostic subsets, autoantibody- 
and autoantigen-targeted therapies, and therapeutic interference 
with chronic inflammation and break of tolerance will set the stage 
for individualized precision medicine, further improvement of 
outcomes, and eventually cure of AAV (20, 22, 23).
PATHOLOGY
ANCA-associated vasculitidies are systemic necrotizing small-
vessel vasculitides, predominantly affecting intraparenchymal 
small arteries, arterioles, capillaries, venules, and less often 
medium-sized arteries and veins. In addition, patients with 
GPA and EGPA display extravascular inflammatory lesions 
with predilection for the upper and/or lower respiratory tract. 
Immunohistology discloses few or no immunoglobulin and 
C3 deposits at inflammatory sites. AAV are hence designated 
pauci-immune vasculitides (1, 24, 25). Swelling, necrosis, and 
detachment of endothelial cells are the earliest histomorphologi-
cal alterations of necrotizing vasculitis. At the vessel wall, both 
marginating and transmigrating neutrophils undergo apoptosis 
and karyorrhexis (leukocytoclasia). In the kidney, degranulation 
of neutrophils induces rupture of glomerular basement mem-
branes and necrosis of adjacent cells, followed by fibrin precipita-
tion. Necrotic debris, fibrin, and proinflammatory factors spill 
into Bowman’s space. Subsequently, monocytes accumulate and 
parietal (Bowman’s) epithelial cells proliferate forming crescents. 
Neutrophils within glomerular lesions also display NETosis, 
i.e., cellular death characterized by the formation of neutrophil 
extracellular traps (NETs) (26). Proinflammatory cytokines, 
chemokines, and complement factors of the alternative pathway 
locate within inflammatory glomerular lesions. Later stages are 
characterized by growing influx of monocytes, macrophages, and 
T- and B-cells. Finally, fibrocellular accumulations progress to 
fibrotic (sclerotic) lesions. Chronic injury occur more frequently 
in MPA (27). Notably, renal outcome and risk of relapse correlate 
with the proportion of sclerotic glomeruli (28, 29) and inversely 
with the proportion of normal glomeruli (30). In GPA, early 
extravascular lesions are characterized by the accumulation 
of neutrophils forming microabscesses. In advanced lesions, 
geographic patterns of necrosis with peripheral accumulation 
of macrophages and giant cells are found. Concomitant cellular 
infiltrates eventually also contain dendritic cells, T- and B-cells, 
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and plasma cells (24, 25). Histopathological classification for 
extravascular granulomatous lesions in GPA has been proposed 
(31). Ectopic lymphatic structures have been found in both 
extravascular granulomatous lesions and glomerulonephritis 
(32, 33). In EGPA, extravascular and vascular lesions are charac-
terized by eosinophilic infiltration (24, 25).
ePiDeMiOLOGY AnD GeneTiC 
BACKGROUnD
A yearly incidence between 10 and 20 per million inhabitants 
and a prevalence of 120 and 140 per million inhabitants has been 
reported for AAV in Europe and the USA. Prevalence doubling 
during the last decade has been attributed to improved outcomes 
(34, 35). Recently, higher incidence of GPA than previously 
reported has been identified in a UK population (36). A cyclical 
pattern of occurrence is observed in GPA, but not MPA (37). 
By contrast, MPA has a higher prevalence than GPA in Japan and 
China (35). Familial cases are rare in AAV (38). While individual 
disease-associated alleles carry modest degrees of risk, multiple 
genetic factors of relatively small effect combine to convey suscep-
tibility to chronic inflammation and autoimmunity (39). Notably, 
the HLA polymorphism shapes self-epitope specific regulatory 
T-cell (Treg) responses, thereby mediating protection or causation 
of autoimmunity (40). Among AAV, GPA displays a remarkable 
HLA-DP association (p = 6.2 × 10−89) (41). The HLA-DPB1*0401 
allele is closely linked to PR3-ANCA+ GPA (p  =  1.2  ×  10−22) 
(42, 43). Reduced HLA-DP protein expression is observed in 
GPA patients with the associated HLA-DP allele (44). By con-
trast, MPO-ANCA+ MPA is HLA-DQ-associated (p = 2.1 × 10−8) 
(41). Furthermore, GPA is associated with polymorphisms of 
α1-anti-trypsin and PR3 encoding genes (41). In EGPA, associa-
tion with HLA-DRB1*04 was reported, whereas HLA-DR*13 is 
underrepresented (45). The IL10.2 haplotype is associated with 
ANCA-negative EGPA and increased interleukin (IL)-10 produc-
tion (46). By contrast, disease-associated PTPN22 R620W allele 
correlates with reduced IL-10 transcription in GPA and MPA 
(47, 48). Aberrant microRNA expression with dysregulation of 
genes involved in inflammation and autoimmunity has been 
reported for various autoimmune diseases (49). In AAV, miRNA 
expression patterns correlate with renal involvement and steroid 
doses (50, 51). Upregulated expression of miR-634 induces a 
proinflammatory phenotype of monocytes in PR3-ANCA+ AVV 
(52). Furthermore, a GPA-specific miRNA expression pattern has 
been found in nasal tissue differentiating GPA from healthy and 
disease controls (53). These findings underscore a multifactorial 
process in which genetic and epigenetic factors play important 
roles in the genesis of AAV (54–57).
BARRieR DYSFUnCTiOn in GPA  
AnD eGPA
Granulomatosis with polyangiitis is known for its propensity 
toward necrotizing neutrophilic granulomatous inflammation of 
the respiratory tract (31). Accordingly, respiratory tract manifes-
tations and flu-like symptoms represent the most frequent initial 
features and affect virtually all patients with GPA during follow-
up in large cohorts (5, 58, 59). Moreover, the so-called “grumbling 
disease” related to persistent ENT disease activity is observed in 
many patients being otherwise in clinical remission and despite 
immunosuppressive treatment (17, 60). Asthma, ENT manifesta-
tions, and eosinophilic pulmonary infiltrates also represent the 
most frequent manifestations in EGPA (7, 61). The nasal mucosa 
displays a unique gene expression signature with differentially 
expressed transcripts of antimicrobial peptides, cytokines, extra-
cellular matrix proteins, and molecules important for epithelial 
barrier integrity in GPA (62, 63). Ciliary motility is severely 
reduced (64). Chronic nasal carriage of Staphylococcus aureus 
is associated with endonasal activity and relapse in GPA and 
facilitated by decreased production of human beta-defensin-3 
and anomalous cytokine expression pattern of nasal epithelial 
cells (65–68). Virulence genes, e.g., genes for pore-forming toxins 
such as leukocidins, may contribute to disease progression and/or 
relapse in PR3-ANCA+ GPA (69). Sensitization to fungi resulting 
in allergic bronchopulmonary aspergillosis may play a role in the 
development of EGPA (70). Moreover, exposure to silica is associ-
ated with increased risk for AAV (71). Altogether, these findings 
suggest a link between respiratory barrier dysfunction, infection, 
and chronic inflammation in GPA and in EGPA (31).
CeLL DeATH AnD CHROniC 
inFLAMMATiOn
Anti-neutrophil cytoplasmic autoantibody-induced pathogenesis 
is linked to neutrophil activation leading to vascular injury, gen-
eration of NETs, apoptosis, and necrosis (25). However, defects 
in the cell death machinery itself can trigger inflammation and 
autoimmunity in AAV in extravascular tissues. Dysregulation in 
neutrophil apoptosis and clearance of apoptotic cells was dem-
onstrated in vitro and in vivo for GPA (72–74). Apoptotic cells 
displaying membrane-located PR3 contribute to non-resolving 
inflammation by disturbing proper clearance (efferocytosis) and 
subsequent proinflammatory polarization of macrophages (72). 
Prolonged survival of neutrophils lead to accumulation within 
inflamed tissue, demonstrated recently in vivo in a human trans-
genic PR3 mouse model (75). Without proper clearing, apoptotic 
neutrophils undergo secondary necrosis with subsequent release 
of proinflammatory cytokines, damage-associated molecular pat-
terns (DAMPs), and potential autoantigens (76). Within necro-
tizing granulomatous inflammation of GPA, release of DAMPs 
such as high-mobility-group-protein B1 (HMGB1) and IL-33 
perpetuate receptor-dependent local auto-amplificatory loops 
(77). HMGB1, also described as endogenous adjuvant (78), is 
expressed together with the autoantigen PR3 on the surface of 
apoptotic neutrophils, potentially contributing to the induction 
of a pathogenic autoimmune response (79). NETosis is linked to 
the pathogenesis of AAV by contributing to endothelial damage, 
stimulation of lymphocytes, and activation of the alternative 
complement cascade (80, 81). Furthermore, ANCA-induced 
NET formation has recently been shown to be controlled by 
caspase-independent form of regulated necrosis, namely necrop-
tosis, in an MPA mouse model (82). Altogether, dysregulation in 
FiGURe 1 | Frequency and phenotype of proteinase 3 (PR3)-specific T-cells determined by flow cytometry. Detection of PR3-specific T-cells within the gated 
CD3+CD8+ T-cell population in a GPA-patient (right dot plot). A negative control (left dot plot). Costimulatory CD28 and CD161 expression on gated PR3-specific 
CD8+ T-cells (A) in comparison to PR3-negative CD8+ T-cells (B) (4).
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the cell death machinery can lead to a necro-inflammatory auto-
amplification loop (83), a relevant pathogenic feature in AAV and 
potential target for future treatment strategies.
ALTeRnATive COMPLeMenT PATHwAY 
ACTivATiOn
Evidence for involvement of the complement system in AAV 
comes from murine models of MPO-ANCA-induced glomerulo-
nephritis and vasculitis, demonstrating activation of the alterna-
tive complement pathway and specifically C5 being essential for 
disease induction (84, 85). This has been confirmed by proteomic 
analysis of kidney biopsies (86). Moreover, in the murine model of 
MPO-ANCA vasculitis, liver-derived C5a is a key mediator (87). 
MPO- and PR3-ANCA-activated neutrophils elicit C5a release. 
Subsequent interaction of C5a with the C5a receptor 1 (C5aR1) 
may represent a proinflammatory amplification loop in AAV 
(88, 89). Consequently, elevated plasma and serum concentrations 
of C5a and C3a have been reported in active AAV, especially MPO-
ANCA+ AAV (90–92). Deposition of complement components is 
detected in human renal biopsies in AAV (93). Similarly, C5aR1 
is expressed scarcely, whereas expression of C5aR2 is upregulated 
in MPO-ANCA+ glomerulonephritis (92). Interestingly, the exact 
role of C5aR2 has not been clearly defined yet. In the context 
of AAV, human neutrophil-expressed C5aR2 interacting with 
C5a seem to play a proinflammatory role (94). However, in the 
murine model of MPO-ANCA-induced glomerulonephritis, 
blocking of C5aR1 with a small molecule antagonist (avacopan) is 
protective, whereas lack of C5aR2 lead to aggravated disease (95). 
The oral C5aR1-antagonist avacopan yields promising results as 
glucocorticoid-sparing agent in two randomized phase II clini-
cal trials (NCT01363388 and NCT02222155) (96). In general, 
tissue expression and function of the anaphylatoxin receptors 
(C5aR1/2) are still poorly understood, specifically in humans 
(97). Therefore, it remains to be examined why results regarding 
tissue expression of C5aR1/2 in MPO-AAV and the function of 
C5aR2 differ between murine and human studies. Altogether, C5a 
can be regarded as one of the central players in the pathogenesis 
of AAV (98). Contribution of the corresponding C5aRs, however, 
needs to be further investigated.
ALTeRATiOnS OF eFFeCTOR AnD Tregs
Disruption of the balance between regulatory and effector 
T-cells and accumulation of effector T-cells in tissues with 
disease propagation favor chronic inflammation and autoim-
munity (99). Alterations of the peripheral T-cell compartment 
have been reported in GPA such as the expansion of circulating 
effector memory T-cells (TEM) including Th1-type CD4+ and 
CD8+ T-cell populations lacking costimulatory CD28 expres-
sion (CD28−), Th17 and Th22 cells, IL-21-producing cells, and 
CD4+CD8+ double-positive cells. Conversely, the percentage of 
circulating naïve T-cells is decreased (4, 100–105). Depletion of 
circulating Vδ2 T-cells, mucosal-associated invariant T-cells, and 
innate lymphoid T-cell subsets have been observed (106, 107). 
Remission is associated with a shift toward circulating total Th2, 
Th9, and Treg populations in GPA (105). Notably, the cytokine 
profile of PR3-specific T-cells is skewed toward Th2-type, Th17, 
and Th22 cells independent of disease activity (102, 108, 109). 
PR3-specific T-cells are CCR7−CD45RA− TEM with either 
“intermediate” CD28+CD27− or “early” CD28+CD27+ phenotype 
(4, 108, 109). They may express the costimulatory c-type lectin 
CD161 (Figure 1).
Percentages of total circulating TEM decrease during active 
disease, suggestive of TEM migration toward inflamed sites 
(101). Accordingly, CD28− TEM are abundant in bronchoalveolar 
fluid, inflammatory lesions, and, during renal activity, in urine 
(100, 110, 111). In EGPA, the frequency of circulating total Th2 
and Th17 cell populations is increased, whereas lower numbers of 
Treg are detected (112–114). Phenotype and function of Treg are 
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altered and impaired, respectively, in AAV (115, 116). Expansion 
of circulating and tissue-resident CD28− TEM lacking IL-2 produc-
tion could favor Treg dysfunction in GPA (100). In line with an 
antigen-driven pathogenesis, oligoclonal T-cell proliferation has 
been reported in AAV previously (117, 118). Expansion of circu-
lating CD28− T-cells has been attributed to latent cytomegalovirus 
(CMV) infection in GPA (119). However, concomitant cellular 
CMV- and Epstein–Barr virus (EBV)-infection rather than sole 
CMV or EBV infection is associated with expansion of CD28− TEM 
(4). Transcriptome analysis suggests pathogen (S. aureus, EBV, 
and others) and inflammation (cytokine and chemokine)-driven 
alterations of the peripheral T-cell compartment linking autoim-
mune disease and infection-triggered pathology in GPA (4).
AnCA iMMUnOGLOBULinS
Myeloperoxidase- and PR3-ANCA are hallmarks of autoimmune 
vasculitis in AAV (Table S1 in Supplementary Material) (23, 120, 121). 
Functionally, numerous in vitro studies demonstrate IgG MPO- 
and PR3-ANCA interaction with neutrophils and monocytes. 
Interaction between circulating ANCA and neutrophils and 
monocytes causing their activation, PR3- and MPO-translocation 
to the cellular surface, microvascular adherence, vascular inflam-
mation, and cell death is known as ANCA-cytokine-sequence 
theory (122). Notably, PR3- and MPO-ANCA display differ-
ences in neutrophil activation, e.g., respiratory burst (123, 124). 
In known or suspected AAV, the revised consensus on the use 
of ANCA testing now recommends high-quality immunoassays 
as primary screening method (13). Regarding IgG MPO-ANCA, 
epitope specificity determines pathogenicity, mainly by identifying 
an epitope of MPO (anti-MPO447-459) that is exclusively linked to 
active MPA (125). IgG MPO-ANCA can be masked by a fragment 
of ceruloplasmin (125). Thus, true ANCA-negative vasculitis is 
considered as being less than 10% using contemporary ANCA 
tests (13, 121). In EGPA, IgA MPO-ANCA can occur together 
with IgG MPO-ANCA, but seem of less value as a biomarker (126). 
Of note, IgG, IgA, and IgM MPO-ANCA representing low-titer 
natural autoantibodies are found in healthy donors (126–128). 
With respect to PR3-ANCA, especially IgG isotypes (122), but 
IgA and IgM as well, have been linked to GPA. IgA PR3-ANCA are 
observed in about a quarter of GPA patients, being less prevalent 
in severe renal disease (129). Transient and recurring presence of 
IgM PR3-ANCA is reported in proportions of two large cohorts 
of patients with GPA or MPA and associated with a higher rate 
of alveolar hemorrhage (130). Similar to MPO-ANCA, IgG, IgA, 
and IgM PR3-ANCA are detected in healthy donors. However, 
the epitope specificity of natural ANCA in healthy donors differs 
from that of pathogenic ANCA in AAV (125, 127–129). Several 
studies indicate that ANCA and other autoantibodies present in 
AAV recognize targets apart from MPO and PR3 (Table S1 in 
Supplementary Material). Some of these studies though still lack 
confirmatory data or functional relevance.
AnCA GLYCOSYLATiOn
Altered Fc N-glycosylation patterns of IgG, differing between 
proinflammatory (agalactosylated) and antiinflammatory 
(galactosylated and sialylated) IgG antibodies (131), may contri-
bute to the pathogenicity of IgG-ANCA and be a useful biomarker. 
Agalactosylation of total IgG has been associated with MPA, 
GPA, and EGPA (132). Instead, sialylation of IgG PR3-ANCA 
inversely correlates with disease activity and ROS production 
by neutrophils in GPA (133). Employing mass spectroscopy, 
reduced galactosylation and sialylation of IgG1 PR3-ANCA or 
total IgG was confirmed (134, 135). IgG-ANCA bind via their 
Fc part to FcγRIIa and FcγRIIIb, thereby co-operating with the 
antigen-binding site in neutrophil activation (136). Alteration 
of IgG-ANCA glycosylation attenuates experimental ANCA-
induced glomerulonephritis (137).
AniMAL MODeLS OF AnCA-inDUCeD 
vASCULiTiS AnD eXTRAvASCULAR 
GRAnULOMATOSiS
While murine models demonstrated convincing evidence for 
MPO-ANCA-induced glomerulonephritis and vasculitis (138), 
it has proven extremely difficult to show pathogenicity of PR3-
ANCA in vivo (139). Transfer of human hematopoietic stem cells 
and anti-PR3 antibodies in NOD-SCID-IL-2Rγ−/− mice induced 
disease manifestations partially resembling systemic vasculitis 
(140), giving a hint of PR3-ANCA pathogenicity. A transgenic 
mouse model expressing human PR3 displays enhanced neutro-
phil survival and accumulation reflecting aspects of granuloma-
tous inflammation in GPA (75). Besides active immunization 
and passive transfer of autoimmunity (141), transplantation of 
GPA tissue into immunodeficient mice provides evidence that 
fibroblasts induce nasal cartilage and bone destruction seen in 
GPA (142).
AUTOReACTive CiRCULATinG  
AnD LeSiOnAL B LYMPHOCYTeS
Increased proportion of circulating matured B-cells recognizing 
PR3 in PR3-ANCA+ AAV (143), presence of ectopic lymphoid 
structures and autoreactive B-cells in inflamed tissue of GPA 
(144, 145) and glomerulonephritis (32) provide a rationale for 
targeting B-cells. B-cell depletion proves to be an efficient therapy 
in AAV (146–148). Although IL-10-producing regulatory B-cells 
(Bregs) and CD24high CD38high Bregs, respectively, are reduced in 
AAV (149–151), their role in AAV remains to be further defined 
as such circulating cells are probably removed by B-cell-depleting 
therapies. Altogether, as possible scenario for ANCA-mediated 
pathogenesis, one could envision that B-cells producing natural 
autoantibodies which recognize PR3, MPO, or other antigens are 
selected in an inflamed microenvironment and mature with the 
help of autoantigen-specific T-cells. Subsequently, this could lead 
to the emergence and survival of pathogenic plasma cells (152) 
producing proinflammatory ANCA.
COnCLUSiOn
Much progress has been achieved in elucidating pathogenetic 
mechanisms in AAV, especially regarding the discovery of links 
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between genetic predispositions and ANCA as well as deciphering 
mostly deleterious functions of PR3- and MPO-ANCA by in vitro 
and in case of the latter by in vivo studies. Future research projects 
should, for instance, focus on investigating the role of microbes 
(bacteria and viruses) in the etiology of AAV. Altogether, a better 
understanding of the complex interplay between endogenous and 
exogenous factors contributing to pathogenic PR3- and MPO-
ANCA may support the development of individualized therapies.
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